Welcome to our dedicated page for KIORA PHARMACEUTICALS SEC filings (Ticker: KPRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Kiora is a clinical-stage biotechnology company developing small-molecule therapies for retinal diseases, including inherited retinal degenerations and inflammatory retinal conditions.
Through this page, users can review Kiora’s periodic and current reports, such as Forms 10-K, 10-Q, and 8-K. Recent Form 8-K filings dated August 8, 2025, and November 7, 2025, reference press releases announcing quarterly financial results and updates on clinical development progress for the company’s Phase 2 trials, ABACUS-2 for KIO-301 and KLARITY for KIO-104. These filings help investors understand how Kiora reports research and development expenses, collaboration revenue and credits, and other items affecting its financial position.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers interpret complex sections of Kiora’s annual reports (Form 10-K) and quarterly reports (Form 10-Q). Users can quickly see how the company describes its retinal disease pipeline, risk factors, collaboration agreements with partners such as Théa Open Innovation and Senju Pharmaceutical, and other material information.
In addition to earnings-related filings, this page can surface other SEC documents relevant to KPRX shareholders, including registration statements and, when applicable, insider transaction reports on Form 4. Real-time updates from the EDGAR system ensure that new Kiora filings appear promptly, while AI-generated overviews provide context so investors can focus on how developments in KIO-301, KIO-104, and related partnerships may affect the company’s overall profile.
Kiora Pharmaceuticals Inc. received an amended Schedule 13G from Rosalind Advisors Inc., Rosalind Master Fund L.P., and portfolio managers Steven Salamon and Gilad Aharon reporting beneficial ownership tied to warrants for up to 464,676 common shares, or 9.9% of the company based on 3,677,935 shares outstanding as of November 5, 2025. These shares are issuable upon exercise of warrants that include a 9.99% beneficial ownership blocker, so as of the December 31, 2025 event date the reporting persons state they could not exercise the warrants. The filers characterize the position as held in the ordinary course of business and state it is not for the purpose of changing or influencing control.
Kiora Pharmaceuticals (KPRX) received an amended Schedule 13G from Nantahala Capital Management and affiliates reporting beneficial ownership of 9.99% of the common stock as of September 30, 2025. The group reports 363,712 shares beneficially owned, which includes 207,285 shares that may be acquired within sixty days through the exercise of warrants.
The reporting persons disclose 0 shares with sole voting or dispositive power and 363,712 shares with shared voting and dispositive power. The filing is certified as securities held in the ordinary course and not for the purpose of changing or influencing control.
Kiora Pharmaceuticals (KPRX) furnished an 8-K announcing it issued a press release with financial results for the quarter ended September 30, 2025 and an update on clinical development progress. The press release is included as Exhibit 99.1.
The company stated the information under Item 2.02, including Exhibit 99.1, is furnished, not filed, and will not be incorporated by reference into other filings unless specifically stated. Kiora’s common stock trades on NASDAQ under the symbol KPRX.
Kiora Pharmaceuticals (KPRX) filed its Q3 2025 Form 10‑Q, showing a small quarterly net income of $26,806, driven by lower operating expenses from collaboration credits and a reduction in contingent consideration fair value. For the nine months, the company recorded a net loss of $4,318,633.
Liquidity remained solid with Cash and Cash Equivalents of $5,508,899 and Short‑Term Investments of $13,866,546. Management states these resources are sufficient to fund planned operations into late 2027. Total assets were $29,863,454 and total liabilities were $7,452,712.
Operating expenses in the quarter benefited from Collaboration Credits of $(1,658,248) and a Change in Fair Value of Contingent Consideration of $(1,721,033), offsetting R&D and G&A. The balance sheet includes Deferred Collaboration Revenue of $1,250,000 tied to an option agreement with Senju.
The company highlighted its TOI license executed in 2024 and ongoing ABACUS‑2 activities. Common shares outstanding were 3,433,491 as of September 30, 2025, and 3,677,935 as of November 5, 2025.
Kiora Pharmaceuticals, Inc. (KPRX) received a Schedule 13G/A reporting that ADAR1-related parties beneficially own 362,527 to 365,179 shares of Common Stock, representing 9.9% of the 3,433,491 shares outstanding as of June 30, 2025. The filing attributes ownership to ADAR1 Capital Management, ADAR1 Capital Management GP, LLC, and Daniel Schneeberger in his managerial and individual capacities. Reported holdings include common shares and shares underlying pre-funded and milestone warrants, while excluding larger blocks of additional warrant shares subject to a 9.99% beneficial ownership limitation. Signatures are dated August 14, 2025.
Nantahala Capital Partners reported beneficial ownership of 189,705 shares of Kiora Pharmaceuticals common stock, representing 5.299% of the outstanding shares as of August 8, 2025. The filing states that 146,533 of those shares may be acquired within 60 days through the exercise of warrants, and Nantahala holds shared voting and dispositive power over the full 189,705 shares while holding no sole voting or dispositive power. The ownership percentage is calculated using 3,433,491 shares outstanding per Kiora's Form 10-Q filed August 8, 2025. The filing includes certifications that the holdings were acquired in the ordinary course of business and not for the purpose of changing or influencing control.
Rosalind Advisors, Rosalind Master Fund L.P. and two affiliated portfolio managers report beneficial ownership of 464,676 shares of Kiora Pharmaceuticals represented by warrants, which the filing treats as issuable Common Stock. The reported position equals 9.9% of the class based on 3,433,491 shares reported by the issuer, and all four reporting persons show 0 sole voting or dispositive power and 464,676 shared voting and dispositive power.
The filing notes these are pre-funded warrants subject to a blocker provision that prevents exercise to the extent it would raise beneficial ownership above 9.99%, so the actual number of Common Shares the reporting persons may hold after applying the blockers is lower than the amounts reported. The reporting parties certify the holdings were acquired in the ordinary course of business and not to influence control of the issuer.
Kiora Pharmaceuticals, Inc. reported via an 8-K that on August 8, 2025 it issued a press release announcing financial results for the quarter ended June 30, 2025 and provided an update on its clinical development progress. The press release is furnished as Exhibit 99.1 and an Inline XBRL cover page is included as Exhibit 104. The filing states that the furnished information, including Exhibit 99.1, is not deemed "filed" under Section 18 and is not incorporated by reference into other Securities Act or Exchange Act filings except where expressly stated.
The report is signed by Melissa Tosca, Chief Financial Officer. No financial line-item figures or clinical data are presented within the 8-K text itself; readers must refer to Exhibit 99.1 for the detailed press release content.
Kiora Pharmaceuticals (KPRX) Q2-25 10-Q highlights:
- No revenue this quarter; prior-year period had $20k and $16.0 million YTD license revenue.
- Operating expenses fell 7% YoY to $2.4 million as higher R&D (+26%) was offset by larger collaboration credits.
- Net loss narrowed slightly to $2.2 million (-$0.54/sh); six-month loss $4.3 million.
- Cash & equivalents $1.0 million; short-term investments $19.6 million; total current assets $24.7 million vs $29.7 million at YE-24. Operating cash burn first half $6.5 million.
- Deferred $1.25 million option fee from Senju for Asian rights to KIO-301; potential total deal value up to $110.8 million.
- Contingent consideration liability $4.6 million.
- Management projects existing funds will finance operations into late-2027.
- 3.43 million shares outstanding; warrant exercises added 0.39 million shares YTD.
Liquidity remains solid, but near-term value hinges on clinical progress and additional partnering.